抑制血管紧张素Ⅱ药物的肾保护研究

被引:6
作者
周楠
沈颖
机构
[1] 首都医科大学附属北京儿童医院
[2] 首都医科大学附属北京儿童医院 北京
[3] 北京
关键词
肾疾病; 血管紧张素Ⅱ; 血管紧张素转化酶抑制药;
D O I
暂无
中图分类号
R692 [肾疾病];
学科分类号
1002 ; 100210 ;
摘要
肾素血管紧张素系统 (RAS)是重要的内分泌系统 ,血管紧张素Ⅱ是该系统最主要的效应因子 ,它影响着肾脏疾病进展的各个环节 ,而越来越多的研究也表明应用血管紧张素转化酶抑制剂 (ACEI)或血管紧张素受体 1拮抗剂 (AT1RA)阻断血管紧张素Ⅱ的效应可以延缓肾脏疾病的发展 ,有效改善预后。本文就阻断血管紧张素Ⅱ药物的肾保护作用及应用研究作一综述。
引用
收藏
页码:807 / 810
页数:4
相关论文
共 20 条
[1]  
The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nabokov A,Amann K,Gassmann P,et al. Nephrology Dialysis Transplantation . 1998
[2]  
Activation of a local tissue angiotensin system in podocytes by mechanical strain. Durvasula RV,Petermann AT,Hiromura K,et al. Kidney International . 2004
[3]  
Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. Graciano ML,Cavaglieri Rde C,Delle H,et al. Journal of the American Society of Nephrology . 2004
[4]  
Proinflammatory actions of angiotensin II. Ruiz-Ortega M,Lorenzo O,Suzuki Y,et al. Current Opinion in Nephrology and Hypertension . 2001
[5]  
Interactions of transforming growth factor-[beta]and angiotensin II in renal fibrosis. Border WA,Noble NA. Journal of Hypertension . 1998
[6]  
Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca- antagonist in hypertensive type 2 diabetic patients with overt nephropathy. Kuriyama S,Tomonari H,Ohtsuka Y,et al. Nippon Jinzo Gakkai Shi . 2003
[7]  
ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection. Laverman GD,Remuzzi G,Ruggenenti P. Journal of the American Society of Nephrology . 2004
[8]  
Additive effects of enalapril and losartan in(mREN-2)27 transgenic rats. Richer C,Bruneval P,Menard J. Journal of Hypertension . 1998
[9]  
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Peters H,Border WA,Noble NA. Kidney International . 1998
[10]  
Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group.Kidney function during and after withdrawal of long- term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Andersen S,Brochner-Mortensen J,Parving HH. Diabetes Care . 2003